By: Huffman, Nelson  S.B. No. 1827
         (In the Senate - Filed March 12, 2021; March 26, 2021, read
  first time and referred to Committee on Finance; April 21, 2021,
  reported adversely, with favorable Committee Substitute by the
  following vote:  Yeas 13, Nays 0; April 21, 2021, sent to printer.)
Click here to see the committee vote
  relating to the creation of the opioid abatement account and to a
  statewide opioid settlement agreement.
         SECTION 1.  Subchapter G, Chapter 403, Government Code, is
  amended by adding Section 403.1044 to read as follows:
         Sec. 403.1044.  OPIOID ABATEMENT ACCOUNT. (a)  The opioid
  abatement account is a dedicated account in the general revenue
         (b)  The account is composed of:
               (1)  money received by the state from any source
  resulting directly or indirectly from an action by the state
  against an opioid manufacturer, an opioid distributor, or another
  person in the opioid industry relating to a violation of state or
  federal law on the manufacture, marketing, distribution, or sale of
  opioids, other than money distributed to a political subdivision of
  the state in accordance with the terms of a settlement agreement or
               (2)  money appropriated or transferred to the account
  by the legislature;
               (3)  gifts and grants contributed to the account; and
               (4)  earnings on the principal of the account.
         (c)  Money in the account may be appropriated only to a state
  agency for the abatement of opioid-related harms.
         (d)  A state agency may use money appropriated to the agency
  from the account only to:
               (1)  prevent opioid use disorder through
  evidence-based education and prevention, such as school-based
  prevention, early intervention, or health care services or programs
  intended to reduce the risk of opioid use by school-age children;
               (2)  support efforts to prevent or reduce deaths from
  opioid overdoses or other opioid-related harms, including through
  increasing the availability or distribution of naloxone or other
  opioid antagonists for use by health care providers, first
  responders, persons experiencing an opioid overdose, families,
  schools, community-based service providers, social workers, or
  other members of the public;
               (3)  create and provide training on the treatment of
  opioid addiction, including the treatment of opioid dependence with
  each medication approved for that purpose by the United States Food
  and Drug Administration, medical detoxification, relapse
  prevention, patient assessment, individual treatment planning,
  counseling, recovery supports, diversion control, and other best
               (4)  provide opioid use disorder treatment for youths
  and adults, with an emphasis on programs that provide a continuum of
  care that includes screening and assessment for opioid use disorder
  and co-occurring behavioral health disorders, early intervention,
  contingency management, cognitive behavioral therapy, case
  management, relapse management, counseling services, and
  medication-assisted treatments;
               (5)  provide patients suffering from opioid dependence
  with access to all medications approved by the United States Food
  and Drug Administration for the treatment of opioid dependence and
  relapse prevention following opioid detoxification, including
  opioid agonists, partial agonists, and antagonists;
               (6)  support efforts to reduce the abuse or misuse of
  addictive prescription medications, including tools used to give
  health care providers information needed to protect the public from
  the harm caused by improper use of those medications;
               (7)  support treatment alternatives that provide both
  psychosocial support and medication-assisted treatments in areas
  with geographical or transportation-related challenges, including
  providing access to mobile health services and telemedicine,
  particularly in rural areas; or
               (8)  further any other purpose related to opioid
  abatement authorized by appropriation.
         SECTION 2.  The attorney general is required to implement a
  provision of this Act only if the legislature appropriates money
  specifically for that purpose. If the legislature does not
  appropriate money specifically for that purpose, the attorney
  general may, but is not required to, implement a provision of this
  Act using other appropriations available for that purpose.
         SECTION 3.  This Act takes effect September 1, 2021.
  * * * * *